Brief by Shorts91 Newsdesk / 04:00am on 05 Jul 2025,Saturday Health & Wellness
India is on the brink of a major public health breakthrough as the Serum Institute of India nears completion of Phase 3 trials for the country’s first homegrown dengue vaccine. Named TetraVax-DV, the vaccine is designed to offer protection against all four serotypes of the dengue virus. The trial, which began in 2023, has enrolled nearly 50% of the targeted participants across 20 sites in both urban and rural areas. Early safety data has shown promising results with no serious adverse effects reported. If successful, the vaccine is expected to be available by 2026, offering a critical tool to combat the seasonal dengue outbreaks that afflict millions in India every year. (PC: The Times of India)
